FISH
Breast Cancer Study Informs Affibody, GE HealthCare's Development Path for HER2 Radiopharmaceutical
Premium
The PET imaging agent 68Ga-ABY-025 could have a leg up over IHC in predicting metastatic breast cancer patients' ability to respond to HER2-targeted treatment.
K36 Therapeutics Treats First Multiple Myeloma Patient in Phase I Trial of KTX-1001
The firm is evaluating its investigational MMSET inhibitor in patients with relapsed or refractory multiple myeloma harboring t(4;14) genetic translocations.
Repeat Biomarker Testing Informs Next Steps for Treatment-Resistant EGFR-Mutant NSCLC Patients
Premium
Studies at ESMO showed the importance of repeat biomarker testing to guide treatment after resistance to AstraZeneca's Tagrisso, but tissue-based testing remains a hindrance.
Celularity Begins Trial of NK Cell Therapy, Herceptin, Keytruda for HER2-Positive Gastric Cancer
The firm believes its engineered off-the-shelf allogeneic placental-derived NK cells can work synergistically with approved antibodies.
FDA Approves Keytruda-Herceptin Combination for HER2-Positive Gastric, Gastroesophageal Cancer
The agency granted accelerated approval to Merck's pembrolizumab plus Herceptin and chemotherapy for patients with advanced, HER2-positive gastric cancer.